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with and without the disease. The patients were randomly selected from a wider sample, but the method of randomisation was not reported. The sites where the study was conducted were not reported. The patients were not followed up after the outcome assessment. The patients completed a self-reported questionnaire and a blood pressure reading was obtained. Electrocardiography was also performed. Two readers coded all the electrocardiagrams (ECGs) and a third coder adjudicated any discrepancies. For echocardiography, a left ventricular ejection fraction (EF) was used as the 'gold' standard for left ventricular function.
Analysis of effectiveness
All patients included in the initial study sample were taken into account when estimating the effectiveness. The health outcomes used in the study were:
the number of patients with LVSD; the sensitivity, specificity, positive and negative predictive values of the alternative predictors evaluated in the analysis (clinical test, ECG, clinical test plus ECG, and BNP); the number of individuals that needed to be examined (NNE) by ECHO to detect one case of LVSD; and the prevalence and identification of factors predicting LVSD in three subgroups of patients.
The three subgroups of patients were:
individuals with ischaemic heart disease (IHD), defined as those with a self-reported myocardial infarction, combined with signs of ischaemia on the ECG or with physician-diagnosed angina and the need for anginal treatment;
high-risk individuals, defined as those with elevated blood pressure and/or ischaemic changes on the ECG; and low-risk individuals, defined as those without the risk factors of the other two groups.
Effectiveness results
The analysis showed that 48 patients (3.8%) had LVSD and 1,209 had an EF of at least 32% (hence, were not at risk of the disease).
In the whole sample, the sensitivity was 85% for the clinical test, 57% for the ECG, 90% for the clinical test plus ECG, and 92% for BNP. The corresponding specificities were 61% (clinical test), 85% (ECG), 56% (clinical test plus ECG) and 53% (BNP), respectively. The positive predictive values were 0.08 for the clinical test, 0.13 for the ECG, 0.07 for the clinical test plus ECG, and 0.07 for BNP. The corresponding negative predictive values were 0.991 (clinical test), 0.980 (ECG), 0.993 (clinical test plus ECG) and 0.994 (BNP), respectively. Thus, LVSD was significantly associated with an abnormal clinical test, ECG abnormalities and elevated plasma BNP.
The NNE was 14%, meaning that 14% ECHOs would be needed to detect one case of LVSD.
When the three subgroups were compared, it was noted that the low-risk group was younger, had more smokers and had less diabetics, cardiovascular medication, cardiac-type dyspnoea and LVSD. It also had a lower median BNP concentration. The prevalence of disease was 0.7% in low-risk patients, 6% in high-risk patients and 19% in ischaemic heart disease patients.
When the predicting factors were analysed, in the subgroup of those with IHD, LVSD was strongly associated with a history of diabetes and modestly with ECG signs of ischaemia. The inclusion of BNP improved the prediction of disease. Among those without symptomatic IHD, diabetes was not associated with LVSD, but high blood pressure and signs of ischaemia on the ECG were significant. The inclusion of BNP also improved disease prediction.
The receiver-operating characteristic curve analysis examined the prediction of LVSD, by BNP, in the three groups. The BNP cut-off point with the highest combination of sensitivity and specificity covered the values from 8 to 19
